Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935574 | 0.78 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL18985115 | 0.77 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL24366690 | 0.75 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL24365656 | 0.75 | BRD4 (0.37) | CHRNB4CHRNA3CHRNA7ALDH1A1TSHR | |
| SCHEMBL30989312 | 0.75 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL895500 | 0.73 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL6558703 | 0.73 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL6797483 | 0.71 | CHRNB4 (0.96) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL433117 | 0.69 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL17398232 | 0.69 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.